Nanjing Vazyme Biotech Co Ltd (SHG:688105) — Market Cap & Net Worth
Market Cap & Net Worth: Nanjing Vazyme Biotech Co Ltd (688105)
Nanjing Vazyme Biotech Co Ltd (SHG:688105) has a market capitalization of $1.65 Billion (CN¥11.27 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #6921 globally and #1449 in its home market, demonstrating a 11.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanjing Vazyme Biotech Co Ltd's stock price CN¥21.79 by its total outstanding shares 516985064 (516.99 Million). Also see Nanjing Vazyme Biotech Co Ltd total assets for a full breakdown of the balance sheet.
Nanjing Vazyme Biotech Co Ltd Market Cap History: 2021 to 2026
Nanjing Vazyme Biotech Co Ltd's market capitalization history from 2021 to 2026. Data shows change from $7.64 Billion to $1.65 Billion (-23.81% CAGR). Also see cash efficiency ratio of Nanjing Vazyme Biotech Co Ltd for how efficiently the company converts equity into cash flow.
Nanjing Vazyme Biotech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanjing Vazyme Biotech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Nanjing Vazyme Biotech Co Ltd for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.10x
Nanjing Vazyme Biotech Co Ltd's market cap is 1.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $7.64 Billion | $1.87 Billion | $678.29 Million | 4.09x | 11.27x |
| 2022 | $3.85 Billion | $3.57 Billion | $594.25 Million | 1.08x | 6.47x |
| 2023 | $2.41 Billion | $1.29 Billion | -$70.96 Million | 1.87x | N/A |
| 2024 | $1.68 Billion | $1.38 Billion | -$18.09 Million | 1.22x | N/A |
| 2025 | $1.51 Billion | $1.38 Billion | -$16.97 Million | 1.10x | N/A |
Competitor Companies of 688105 by Market Capitalization
Companies near Nanjing Vazyme Biotech Co Ltd in the global market cap rankings as of September 21, 2026. Review 688105 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Nanjing Vazyme Biotech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Nanjing Vazyme Biotech Co Ltd Historical Marketcap From 2021 to 2026
Between 2021 and today, Nanjing Vazyme Biotech Co Ltd's market cap moved from $7.64 Billion to $ 1.65 Billion, with a yearly change of -23.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.65 Billion | +8.84% |
| 2025 | CN¥1.51 Billion | -9.70% |
| 2024 | CN¥1.68 Billion | -30.38% |
| 2023 | CN¥2.41 Billion | -37.38% |
| 2022 | CN¥3.85 Billion | -49.68% |
| 2021 | CN¥7.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 21st, 2026 the market cap of Nanjing Vazyme Biotech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.65 Billion USD |
| MoneyControl | $1.65 Billion USD |
| MarketWatch | $1.65 Billion USD |
| marketcap.company | $1.65 Billion USD |
| Reuters | $1.65 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanjing Vazyme Biotech Co Ltd
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real… Read more